Compare Enveric Biosciences Inc (ENVB) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs McCormick & Company, Incorporated — how do they compare? Enveric Biosciences Inc trades at $1.37 (market cap $5.32M), while McCormick & Company, Incorporated trades at $52.79 (market cap $13.70B). The key difference: McCormick & Company, Incorporated is far larger — about 2575.2× Enveric Biosciences Inc's market cap, and McCormick & Company, Incorporated pays a 3.77% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | MKC | |
|---|---|---|
Market Cap | $5.32M | $13.70B |
Sector | Health | Consumer Staples |
52-Week High | $17.40 | $72.81 |
52-Week Low | $1.28 | $45.60 |
Enterprise Value | $408.82K | $18.30B |
Dividend Yield | — | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
MKC trades at $52.44, down 0.78% for the day, with a neutral technical signal. The stock shows strong profitability with a 21.91% net income margin and 25.7% ROE, while trading at a P/E of 8.47. Recent Q2 2026 earnings beat estimates, and the company is pursuing a transformative acquisition of Unilever's food business, which could significantly expand its scale.
The outlook is mixed; the potential Unilever deal offers substantial growth, but soft consumer volumes and modest organic growth present near-term risks. Analyst consensus is a 'Hold' with a $59.67 price target, implying potential upside. Key risks include integration challenges from the acquisition and competitive pressures in the consumer segment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
